Bli medlem
Bli medlem

Du är här

2016-08-25

Biotie Therapies Oyj: THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP.

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 25 August 2016, at 2.15
p.m. (EET)

THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF
BIOTIE THERAPIES CORP.

The Listing Committee of Nasdaq Helsinki Ltd ("Nasdaq Helsinki
") has today, 25 August 2016, resolved to terminate public trading and to
delist Biotie Therapies Corp.'s (Nasdaq Helsinki: BTH1V) ("Biotie
") shares from the official list of Nasdaq Helsinki after Acorda Therapeutics,
Inc. (Nasdaq: ACOR) ("Acorda
") has gained title to all outstanding and issued shares in Biotie in the
compulsory redemption proceedings in accordance with the Finnish Companies
Act.

The decision of the Listing Committee is made pursuant to the application
filed by Biotie with the Listing Committee on 18 August 2016 to terminate
public trading in Biotie shares and to delist the shares from the official
list of Nasdaq Helsinki. In the application, Biotie requested that the
quotation of the Biotie shares on the official list of Nasdaq Helsinki is
terminated as soon as possible after Acorda has gained title to the shares in
Biotie that are subject to the redemption proceedings in accordance with the
Finnish Companies Act.

The transfer of title to Acorda and the subsequent termination of public
trading and delisting of Biotie shares will be announced in due course
through a separate stock exchange release.

Turku, 25 August 2016

Biotie Therapies Corp.
Antero Kallio
CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie is a biopharmaceutical company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has
delivered Selincro (nalmefene) for alcohol dependence, which received
European marketing authorization in 2013 and is currently being rolled out
across Europe by partner H. Lundbeck A/S. The current development products
include tozadenant for Parkinson's disease, which is in Phase 3 development,
and two additional compounds which are in Phase 2 development for cognitive
disorders including Parkinson's disease dementia, and primary sclerosing
cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a part of
Acorda Therapeutics Inc. Group ("Acorda") and its shares, excluding of those
owned by Acorda, are currently subject to a redemption process in accordance
with the Finnish Companies Act.

For more information, please visit www.biotie.com.

INFORMATION REGARDING ACORDA

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on
developing therapies that restore function and improve the lives of people
with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson's disease, post-stroke
walking difficulties, migraine, and multiple sclerosis. Acorda markets three
FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release
Tablets, 10 mg.

For more information, please visit www.acorda.com.

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.